UEG Week Recordings UEG Week Posters Online courses Guidelines Mistakes in... Podcasts Webinars
new
Gut Guide online
Visit ueg.eu Create myUEG account Log In
Visit ueg.eu Create myUEG account Log In

Filters:

UEG Online Course
not accredited
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

A primer in capsule endoscopy

Uwe Seitz

Summary

AI Generated

This online course provides a comprehensive introduction to capsule endoscopy, covering technique, reporting software, complications, and clinical applications through eight illustrative cases.

  • Capsule endoscopy allows visualisation of the entire small intestine and is generally safe, well tolerated, and less invasive than traditional endoscopy
  • Common indications for capsule endoscopy include occult bleeding and iron-deficiency anaemia
  • The course covers use of capsule reporting software, management of common complications, and interpretation of common pathologies encountered during capsule endoscopy
  • Learning objectives emphasise the importance of thorough patient history knowledge when interpreting findings and understanding the interface between capsule endoscopy and other diagnostic procedures including upper digestive endoscopy and enteroscopy
  • The course is designed for accredited gastroenterologists, gastroenterologists in training, radiologists, and gastrointestinal surgeons
Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Overview

Capsule endoscopy (also known as wireless capsule endoscopy or video capsule endoscopy) allows visualisation of the entire small intestine. The procedure has gained popularity because it is not invasive in the same way as traditional endoscopy and it is generally safe and well tolerated. Common indications for the use of capsule endoscopy include occult bleeding and iron-deficiency anaemia, among others.

This online course aims to provide a full introduction to capsule endoscopy, capsule reporting software and the potential complications that may be encountered. Eight cases are used to illustrate the role of capsule endoscopy.  The course is based on a presentation (with 35 accompanying slides) given by Uwe Seitz as part of a practical skills training session recorded in June 2015 at the United European Gastroenterology Summer School in Prague, Czech Republic.

Learning objectives

  • Understand the basics of how to use capsule reporting software.
  • Know how to deal with the most common complications of capsule endoscopy.
  • Be aware of the most common indications for capsule endoscopy.
  • Understand the common pathologies encountered at capsule endoscopy.
  • Be aware of further investigations that may be recommended following the identification of small-bowel lesions.
  • Appreciate the need for a thorough knowledge of the patient’s history when interpreting capsule findings.
  • Know the role of capsule endoscopy in the investigation of patients with iron-deficiency anaemia of unknown origin (both obscure occult bleeding and overt occult bleeding).
  • Understand the interface between capsule endoscopy and upper digestive endoscopy and enteroscopy.

Target audience

Accredited Gastroenterologists, Gastroenterologists in training, Radiologists and GI surgeons. 

Event

A primer in capsule endoscopy

Topics

Endoscopy

Accreditation status

not accredited

Duration

1 hour

Published

2015

More Like This:

Summary: Strategies in proctology: From diagnosis to multidisciplinary management

Summary: Strategies in proctology: From diagnosis to multidisciplinary management

Ugo Grossi Ugo Grossi

The use of PREMs and PROMs to improve the care of patients with liver disease

The use of PREMs and PROMs to improve the care of patients with liver disease

Maria Hjorth Maria Hjorth

Targeting immunometabolism with medical therapies in IBD

Targeting immunometabolism with medical therapies in IBD

Virginia Solitano Virginia Solitano

DECIPHERING THE PRODROME OF INFLAMMATORY BOWEL DISEASE UP TO 10 YEARS BEFORE DISEASE ONSET BY MASSIVELY PARALLEL SEROLOGY

DECIPHERING THE PRODROME OF INFLAMMATORY BOWEL DISEASE UP TO 10 YEARS BEFORE DISEASE ONSET BY MASSIVELY PARALLEL SEROLOGY

Thomas Vogl Thomas Vogl, Saurabh Mehandru, Jean-Frédéric Colombel, Mayte Suarez-Fariñas, Joana Torres, Francesca Petralia, Sacha Gnjatic, Chad K. Porter, Thierry Dervieux, Renee M. Laird, Mark S. Riddle, Jared S. Magee, Melanie Prinzensteiner, Alexandra E. Livanos, Gabriel Innocenti, Arno R. Bourgonje

BUDESONIDE ORAL SUSPENSION IMPROVES HISTOLOGICAL AND ENDOSCOPIC PARAMETERS AND ESOPHAGEAL DISTENSIBILITY IN PEDIATRIC EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 2/3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (PEDEOS-1)

BUDESONIDE ORAL SUSPENSION IMPROVES HISTOLOGICAL AND ENDOSCOPIC PARAMETERS AND ESOPHAGEAL DISTENSIBILITY IN PEDIATRIC EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 2/3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (PEDEOS-1)

Jorge Amil Dias Jorge Amil Dias, Stephan Buderus, Ralph Mueller, Sarah Burrack, Michael Vieth, Noam Zevit, Carolina Gutiérrez Junquera, Michiel van Wijk, Johanna Escher, Shoma Dutt, Marcus Karl-Heinz Auth, Alexandra Papadopoulou, Henedina Antunes, Alfredo J. Lucendo

Association between pancreatic adenocarcinoma and organochlorine pesticides

Association between pancreatic adenocarcinoma and organochlorine pesticides

Ahsen Ustaoglu Ahsen Ustaoglu, Mathias Brugel

UEG Presentation
New
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
Summary: Strategies in proctology: From diagnosis to multidisciplinary management

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Summary: Strategies in proctology: From diagnosis to multidisciplinary management

Ugo Grossi 1

Affiliations

1 Humanitas Gavazzeni, Bergamo, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Event

Postgraduate Teaching Programme Barcelona 2026

Topics

Surgery Colorectal

Session

Strategies in proctology: From diagnosis to multidisciplinary management

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Summary: Strategies in proctology: From diagnosis to multidisciplinary management

Summary: Strategies in proctology: From diagnosis to multidisciplinary management

Ugo Grossi Ugo Grossi

The use of PREMs and PROMs to improve the care of patients with liver disease

The use of PREMs and PROMs to improve the care of patients with liver disease

Maria Hjorth Maria Hjorth

Targeting immunometabolism with medical therapies in IBD

Targeting immunometabolism with medical therapies in IBD

Virginia Solitano Virginia Solitano

DECIPHERING THE PRODROME OF INFLAMMATORY BOWEL DISEASE UP TO 10 YEARS BEFORE DISEASE ONSET BY MASSIVELY PARALLEL SEROLOGY

DECIPHERING THE PRODROME OF INFLAMMATORY BOWEL DISEASE UP TO 10 YEARS BEFORE DISEASE ONSET BY MASSIVELY PARALLEL SEROLOGY

Thomas Vogl Thomas Vogl, Saurabh Mehandru, Jean-Frédéric Colombel, Mayte Suarez-Fariñas, Joana Torres, Francesca Petralia, Sacha Gnjatic, Chad K. Porter, Thierry Dervieux, Renee M. Laird, Mark S. Riddle, Jared S. Magee, Melanie Prinzensteiner, Alexandra E. Livanos, Gabriel Innocenti, Arno R. Bourgonje

BUDESONIDE ORAL SUSPENSION IMPROVES HISTOLOGICAL AND ENDOSCOPIC PARAMETERS AND ESOPHAGEAL DISTENSIBILITY IN PEDIATRIC EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 2/3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (PEDEOS-1)

BUDESONIDE ORAL SUSPENSION IMPROVES HISTOLOGICAL AND ENDOSCOPIC PARAMETERS AND ESOPHAGEAL DISTENSIBILITY IN PEDIATRIC EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 2/3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (PEDEOS-1)

Jorge Amil Dias Jorge Amil Dias, Stephan Buderus, Ralph Mueller, Sarah Burrack, Michael Vieth, Noam Zevit, Carolina Gutiérrez Junquera, Michiel van Wijk, Johanna Escher, Shoma Dutt, Marcus Karl-Heinz Auth, Alexandra Papadopoulou, Henedina Antunes, Alfredo J. Lucendo

Association between pancreatic adenocarcinoma and organochlorine pesticides

Association between pancreatic adenocarcinoma and organochlorine pesticides

Ahsen Ustaoglu Ahsen Ustaoglu, Mathias Brugel

UEG Presentation
New
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
The use of PREMs and PROMs to improve the care of patients with liver disease

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

The use of PREMs and PROMs to improve the care of patients with liver disease

Maria Hjorth 1

Affiliations

1 None, None, Sweden

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Event

UEG Week Barcelona 2026

Topics

Nurses

Session

Innovative approaches in liver disease management – in cooperation with EASL nurses and AHP taskforce

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Summary: Strategies in proctology: From diagnosis to multidisciplinary management

Summary: Strategies in proctology: From diagnosis to multidisciplinary management

Ugo Grossi Ugo Grossi

The use of PREMs and PROMs to improve the care of patients with liver disease

The use of PREMs and PROMs to improve the care of patients with liver disease

Maria Hjorth Maria Hjorth

Targeting immunometabolism with medical therapies in IBD

Targeting immunometabolism with medical therapies in IBD

Virginia Solitano Virginia Solitano

DECIPHERING THE PRODROME OF INFLAMMATORY BOWEL DISEASE UP TO 10 YEARS BEFORE DISEASE ONSET BY MASSIVELY PARALLEL SEROLOGY

DECIPHERING THE PRODROME OF INFLAMMATORY BOWEL DISEASE UP TO 10 YEARS BEFORE DISEASE ONSET BY MASSIVELY PARALLEL SEROLOGY

Thomas Vogl Thomas Vogl, Saurabh Mehandru, Jean-Frédéric Colombel, Mayte Suarez-Fariñas, Joana Torres, Francesca Petralia, Sacha Gnjatic, Chad K. Porter, Thierry Dervieux, Renee M. Laird, Mark S. Riddle, Jared S. Magee, Melanie Prinzensteiner, Alexandra E. Livanos, Gabriel Innocenti, Arno R. Bourgonje

BUDESONIDE ORAL SUSPENSION IMPROVES HISTOLOGICAL AND ENDOSCOPIC PARAMETERS AND ESOPHAGEAL DISTENSIBILITY IN PEDIATRIC EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 2/3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (PEDEOS-1)

BUDESONIDE ORAL SUSPENSION IMPROVES HISTOLOGICAL AND ENDOSCOPIC PARAMETERS AND ESOPHAGEAL DISTENSIBILITY IN PEDIATRIC EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 2/3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (PEDEOS-1)

Jorge Amil Dias Jorge Amil Dias, Stephan Buderus, Ralph Mueller, Sarah Burrack, Michael Vieth, Noam Zevit, Carolina Gutiérrez Junquera, Michiel van Wijk, Johanna Escher, Shoma Dutt, Marcus Karl-Heinz Auth, Alexandra Papadopoulou, Henedina Antunes, Alfredo J. Lucendo

Association between pancreatic adenocarcinoma and organochlorine pesticides

Association between pancreatic adenocarcinoma and organochlorine pesticides

Ahsen Ustaoglu Ahsen Ustaoglu, Mathias Brugel

UEG Presentation
New
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
Targeting immunometabolism with medical therapies in IBD

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Targeting immunometabolism with medical therapies in IBD

Virginia Solitano 1

Affiliations

1 IRCCS Ospedale San Raffaele, Milan, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Event

UEG Week Barcelona 2026

Topics

Small Intestine & Nutrition Mechanisms & Personalised Medicine Immunology IBD

Session

Metabolic aspects of immunomodulatory IBD therapy

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Summary: Strategies in proctology: From diagnosis to multidisciplinary management

Summary: Strategies in proctology: From diagnosis to multidisciplinary management

Ugo Grossi Ugo Grossi

The use of PREMs and PROMs to improve the care of patients with liver disease

The use of PREMs and PROMs to improve the care of patients with liver disease

Maria Hjorth Maria Hjorth

Targeting immunometabolism with medical therapies in IBD

Targeting immunometabolism with medical therapies in IBD

Virginia Solitano Virginia Solitano

DECIPHERING THE PRODROME OF INFLAMMATORY BOWEL DISEASE UP TO 10 YEARS BEFORE DISEASE ONSET BY MASSIVELY PARALLEL SEROLOGY

DECIPHERING THE PRODROME OF INFLAMMATORY BOWEL DISEASE UP TO 10 YEARS BEFORE DISEASE ONSET BY MASSIVELY PARALLEL SEROLOGY

Thomas Vogl Thomas Vogl, Saurabh Mehandru, Jean-Frédéric Colombel, Mayte Suarez-Fariñas, Joana Torres, Francesca Petralia, Sacha Gnjatic, Chad K. Porter, Thierry Dervieux, Renee M. Laird, Mark S. Riddle, Jared S. Magee, Melanie Prinzensteiner, Alexandra E. Livanos, Gabriel Innocenti, Arno R. Bourgonje

BUDESONIDE ORAL SUSPENSION IMPROVES HISTOLOGICAL AND ENDOSCOPIC PARAMETERS AND ESOPHAGEAL DISTENSIBILITY IN PEDIATRIC EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 2/3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (PEDEOS-1)

BUDESONIDE ORAL SUSPENSION IMPROVES HISTOLOGICAL AND ENDOSCOPIC PARAMETERS AND ESOPHAGEAL DISTENSIBILITY IN PEDIATRIC EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 2/3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (PEDEOS-1)

Jorge Amil Dias Jorge Amil Dias, Stephan Buderus, Ralph Mueller, Sarah Burrack, Michael Vieth, Noam Zevit, Carolina Gutiérrez Junquera, Michiel van Wijk, Johanna Escher, Shoma Dutt, Marcus Karl-Heinz Auth, Alexandra Papadopoulou, Henedina Antunes, Alfredo J. Lucendo

Association between pancreatic adenocarcinoma and organochlorine pesticides

Association between pancreatic adenocarcinoma and organochlorine pesticides

Ahsen Ustaoglu Ahsen Ustaoglu, Mathias Brugel

UEG Presentation
New
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
DECIPHERING THE PRODROME OF INFLAMMATORY BOWEL DISEASE UP TO 10 YEARS BEFORE DISEASE ONSET BY MASSIVELY PARALLEL SEROLOGY

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

DECIPHERING THE PRODROME OF INFLAMMATORY BOWEL DISEASE UP TO 10 YEARS BEFORE DISEASE ONSET BY MASSIVELY PARALLEL SEROLOGY

Arno R. Bourgonje 1,2, Gabriel Innocenti 3, Alexandra E. Livanos 2, Melanie Prinzensteiner 3, Jared S. Magee 4, Mark S. Riddle 5, Renee M. Laird 6, Thierry Dervieux 7, Chad K. Porter 8, Sacha Gnjatic 2, Francesca Petralia 2, Joana Torres 9, Mayte Suarez-Fariñas 2, Thomas Vogl 3, Jean-Frédéric Colombel 2, Saurabh Mehandru 2

Affiliations

1 University Medical Center Groningen, Groningen, Netherlands

2 Icahn School of Medicine at Mount Sinai, New York, United States

3 Medical University of Vienna, Vienna, Austria

4 Walter Reed National Military Medical Center, Bethesda, United States

5 University of Nevada, Reno, United States

6 Naval Medical Research Center, Silver Spring, United States

7 Prometheus Labs, Irvine, United States

8 Henry M. Jackson Foundation for Military Medicine, Bethesda, United States

9 Hospital Beatriz Ângelo & Hospital da Luz, Lisbon, Portugal

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Defining immune dysregulation during the asymptomatic prodrome of immune-mediated diseases offers opportunities for early disease detection and interception. In inflammatory bowel disease (IBD), prodromal immune changes remain poorly characterized. This study aimed to define the antigen specificities, breadth, longitudinal stability, and predictive ability of pre-clinical serum antibody repertoires using a novel, high-throughput phage-display immunoprecipitation sequencing assay (PhIP-Seq).

Aims & Methods

Longitudinal serum samples from active component US military personnel collected at diagnosis and at ~10, ~4, and ~2 years pre-Crohn’s disease (CD, n=200), pre-ulcerative colitis (UC, n=200) and in age- and sex-matched healthy controls (HC, n=100) were analysed. Serum antibody repertoires were defined against 357,000 microbial-, viral-, food-, and immune-associated peptide antigens. Logistic regression analyses were performed to identify differentially abundant antibodies per timepoint. Temporal stability of antibodies was assessed using point-biserial correlations. Longitudinal sample analyses were performed using generalized linear mixed-effects models. Finally, machine learning models, including tree-based ensemble methods, were used for prediction of disease.

Results

Across 2,000 samples, 123,980 unique antibodies were identified. Antibody repertoire diversity was significantly lower in pre-CD (P<0.05) and pre-UC (P<0.001) sera compared to HC sera. Up to ~4 years pre-diagnosis, pre-CD samples exhibited more fluctuations in antibody repertoires compared to pre-UC and HC samples (both P<0.001). Distinct antibody responses were evident up to 10 years pre-CD and pre-UC versus HCs. Differential analyses revealed elevated herpesvirus-directed responses (notably Epstein-Barr virus and cytomegalovirus) and anti-flagellin antibodies, particularly in individuals who later developed complicated or ileal disease. In contrast, responses to encapsulated bacteria (e.g., Streptococcus pneumoniae, Haemophilus, Neisseria) progressively declined towards diagnosis. Pre-UC individuals exhibited rising antibody responses against herpesviruses and autoantigens including MAP-kinase-activating death domain (MADD) protein and reduced reactivity against encapsulated pathogens (e.g., Streptococcus pneumoniae- and Haemophilus influenzae). Machine learning models integrating antibody repertoires discriminated future CD (AUC=0.90) and UC (AUC=0.84) from controls up to 10 years pre-diagnosis. Additionally, antibody repertoires differentiated complicated from non-complicated CD up to ~10 years pre-diagnosis with high accuracy (AUC=0.85).

Conclusion

Antibody profiling delineates a previously unappreciated landscape of serological responses against microbial and non-microbial antigens up to 10 years before disease onset in patients with CD and UC. Large-scale serological profiling of archived pre-diagnostic samples enables systematic detection of disease-specific immune trajectories years before IBD onset, providing a scalable framework for early risk stratification and biomarker discovery.

Disclosure

The corresponding author confirms on behalf of all authors that there have been no involvements that might raise the question of bias in the work reported or in the conclusions, implications, or opinions stated. SM reports receiving research grants from Genentech and Takeda; receiving payment for lectures from Takeda, Genentech, Morphic; and receiving consulting fees from Takeda, Morphic, Ferring, and Arena Pharmaceuticals. ARB reports receiving research grants from Janssen Pharmaceuticals and received speaker’s fees from Ferring and AbbVie. SG reports other research funding from Genentech, Boehringer-Ingelheim, EMD Serono, Takeda, and Regeneron. JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals, Takeda and Bristol Myers Squibb; receiving payment for lectures from AbbVie, and Takeda; receiving consulting fees from AbbVie, Amgen, AnaptysBio, Allergan, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Celltrion, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Glaxo Smith Kline, Genentech (Roche), Janssen Pharmaceuticals, Kaleido Biosciences, Immunic, Invea, Iterative Scopes, Merck, Landos, Microba Life Science, Novartis, Nautilus, Otsuka Pharmaceutical, Pfizer, Protagonist Therapeutics, Prometheus, Sanofi, Seres, Takeda, Teva, TiGenix, Vifor; and hold stock options in Intestinal Biotech Development. All other authors have no conflicts of interest to declare.

Event

UEG Week Barcelona 2026

Topics

Colorectal IBD

Submission format

Abstract

Session

IBD diagnostics: In search of optimal implementation

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Summary: Strategies in proctology: From diagnosis to multidisciplinary management

Summary: Strategies in proctology: From diagnosis to multidisciplinary management

Ugo Grossi Ugo Grossi

The use of PREMs and PROMs to improve the care of patients with liver disease

The use of PREMs and PROMs to improve the care of patients with liver disease

Maria Hjorth Maria Hjorth

Targeting immunometabolism with medical therapies in IBD

Targeting immunometabolism with medical therapies in IBD

Virginia Solitano Virginia Solitano

DECIPHERING THE PRODROME OF INFLAMMATORY BOWEL DISEASE UP TO 10 YEARS BEFORE DISEASE ONSET BY MASSIVELY PARALLEL SEROLOGY

DECIPHERING THE PRODROME OF INFLAMMATORY BOWEL DISEASE UP TO 10 YEARS BEFORE DISEASE ONSET BY MASSIVELY PARALLEL SEROLOGY

Thomas Vogl Thomas Vogl, Saurabh Mehandru, Jean-Frédéric Colombel, Mayte Suarez-Fariñas, Joana Torres, Francesca Petralia, Sacha Gnjatic, Chad K. Porter, Thierry Dervieux, Renee M. Laird, Mark S. Riddle, Jared S. Magee, Melanie Prinzensteiner, Alexandra E. Livanos, Gabriel Innocenti, Arno R. Bourgonje

BUDESONIDE ORAL SUSPENSION IMPROVES HISTOLOGICAL AND ENDOSCOPIC PARAMETERS AND ESOPHAGEAL DISTENSIBILITY IN PEDIATRIC EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 2/3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (PEDEOS-1)

BUDESONIDE ORAL SUSPENSION IMPROVES HISTOLOGICAL AND ENDOSCOPIC PARAMETERS AND ESOPHAGEAL DISTENSIBILITY IN PEDIATRIC EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 2/3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (PEDEOS-1)

Jorge Amil Dias Jorge Amil Dias, Stephan Buderus, Ralph Mueller, Sarah Burrack, Michael Vieth, Noam Zevit, Carolina Gutiérrez Junquera, Michiel van Wijk, Johanna Escher, Shoma Dutt, Marcus Karl-Heinz Auth, Alexandra Papadopoulou, Henedina Antunes, Alfredo J. Lucendo

Association between pancreatic adenocarcinoma and organochlorine pesticides

Association between pancreatic adenocarcinoma and organochlorine pesticides

Ahsen Ustaoglu Ahsen Ustaoglu, Mathias Brugel

UEG Poster
New
Audio / Video Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

BUDESONIDE ORAL SUSPENSION IMPROVES HISTOLOGICAL AND ENDOSCOPIC PARAMETERS AND ESOPHAGEAL DISTENSIBILITY IN PEDIATRIC EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 2/3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (PEDEOS-1)

Alfredo J. Lucendo 1, Henedina Antunes 2, Alexandra Papadopoulou 3, Marcus Karl-Heinz Auth 4, Shoma Dutt 5, Johanna Escher 6, Michiel van Wijk 7, Carolina Gutiérrez Junquera 8, Noam Zevit 9, Michael Vieth 10, Sarah Burrack 11, Ralph Mueller 11, Stephan Buderus 12, Jorge Amil Dias 13

Affiliations

1 Hospital General de Tomelloso, Madrid, Spain

2 Pediatric Gastrenterology Unit; 2ca-ulsbraga;icvs;icvs-3b's La;medical School, Uminho, Braga, Portugal

3 Children's Hospital Agia Sofia, Athens, Greece

4 University of Liverpool, Liverpool, United Kingdom

5 The Children’ Hospital at Westmead, Westmead, Australia

6 Erasmus Medical Center, Rotterdam, Netherlands

7 Emma Childrens Hospital, AMC, Amsterdam, Netherlands

8 Autonomous University de Madrid, Madrid, Spain

9 Schneider Childrens Medical Center of Israel, Petah-Tikva, Israel

10 Klinikum Bayreuth Abt. Pathology, Bayreuth, Germany

11 Dr. Falk Pharma GmbH, Freiburg, Germany

12 GFO-Kliniken Bonn, St. Marien-Hospital, Bonn, Germany

13 Hospital Lusíadas, Porto, Portugal

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus with increasing incidence across all age groups and limited treatment options for pediatric patients. Recently, a novel budesonide oral suspension (BOS) was shown in a phase 2/3 trial to be superior to placebo for inducing both histological remission and clinical response after 12 weeks of treatment in EoE patients ages 2 to 17 years. Here, we report endoscopic and esophageal distensibility outcomes from two sequential 12-week induction phases.

Aims & Methods

PEDEOS-1 was a phase 2/3 pivotal trial of BOS with a 12-week randomized, placebo-controlled, double-blind induction (DB) phase, followed by a 12-week open-label induction (OLI) phase for patients who did not achieve response in the DB phase, and finally a 24-week open-label extension phase. EoE patients ages of 2 to 17 were randomly assigned in a 1:1:1 ratio to an age-adapted high-dose BOS regimen, low-dose BOS regimen, or placebo in the DB phase. All patients in the OLI phase received BOS-H. Endoscopies were performed at the start and end of both phases. Histological and endoscopic endpoints included peak eosinophil (eos) counts per mm2 high-power field (hpf), EoE Endoscopic Reference Score (EREFS), EoE Histological Stage Score (EoEHSS) grade and stage scores, and esophageal diameter measured by Endoluminal Functional Lumen Imaging Probe (EndoFLIP).

Results

A total of 76 patients (ages 2-11 y: n=35; 12-17 y: n=41) enrolled in the trial, and 45 patients (2-11 y: 22; 12-17 y: 23) participated in the OLI phase. At week 12 of the DB phase, peak eos/mm2 hpf decreased by -229 with BOS-H, -170 with BOS-L, and -8 with placebo (p<0.0001 for both groups vs. placebo, Table 1). Among patients who proceeded to the OLI phase, changes in peak eos were -27 for prior BOS-H patients, -124 for prior BOS-L patients, and -221 for placebo patients. Similar dose-dependent decreases were observed in the EoEHSS stage and grade scores. Total EREFS scores improved to a similar extent with BOS-H and BOS-L during the DB phase, with further improvements over the 12-week OLI phase. In the subgroup of patients evaluated for esophageal distensibility by EndoFLIP measurement, esophageal diameter increased by 1.4 mm with BOS-H, 0.2 mm with BOS-L, and decreased by -1.2 mm with placebo during the 12-week DB phase.

1 p-values were only calculated for the change in peak eos during the DB phase
2 DB phase baseline or OLI phase baseline, respectively

Double-Blind induction (DB, 12 weeks)
Open-Label Induction (OLI, 12 weeks)

BOS-H
(n=26)
BOS-L
(n=26)
Placebo
(n=24)
BOS-H >
BOS-H
(n=8)
BOS-L >
BOS-H
(n=14)
Placebo >
BOS-H
(n=23)
Peak eos/mm² hpf
Mean (SD) at baseline1
Mean (SD) at week 12 (LOCF)
Mean change from baseline to week 12 (LOCF)
p-value vs. placebo1

238 (123.1)
10 (40.4)
-229
p<0.0001

246 (108.7)
76 (153.1)
-170
p<0.0001

239 (122.1)
228 (155.6)
-8

36 (74.0)
7 (20.1)
-27

140 (188.0)
16 (46.7)
-124

228 (155.6)
24 (83.9)
-221
EoEHSS grade score
Mean (SD) at baseline2
Mean (SD) at week 12 (LOCF)
Mean change from baseline to week 12 (LOCF)

0.50 (0.16)
0.10 (0.12)
-0.41 (0.19)
n=25

0.50 (0.14)
0.23 (0.24)
-0.27 (0.31)

0.55 (0.16)
0.50 (0.13)
-0.06 (0.18)
n=22

0.17 (0.19)
0.03 (0.05)
-0.14 (0.17)
n=7

0.37 (0.28)
0.12 (0.24)
-0.25 (0.29)

0.49 (0.13)
0.10 (0.12)
-0.41 (0.16)
n=22
EoEHSS stage score
Mean (SD) at baseline2
Mean (SD) at week 12 (LOCF)
Mean change from baseline to week 12 (LOCF)

0.50 (0.13)
0.12 (0.13)
-0.38 (0.16)
n=25

0.50 (0.09)
0.21 (0.25)
-0.28 (0.28)

0.53 (0.13)
0.49 (0.12)
-0.05 (0.14)
n=20

0.23 (0.17)
0.04 (0.06)
-0.18 (0.18)
n=7

0.36 (0.28)
0.09 (0.17)
-0.27 (0.27)

0.49 (0.12)
0.11 (0.16)
-0.40 (0.16)
n=22
EREFS total score
Mean (SD) at baseline2
Mean (SD) at week 12 (LOCF)
Mean change from baseline to week 12 (LOCF)

3.2 (1.0)
0.9 (1.2)
-2.2 (1.5)
n=23

3.6 (1.4)
1.2 (1.3)
-2.4 (1.7)
n=25

3.2 (1.8)
3.5 (1.6)
0.4 (2.0)
n=22

1.9 (1.6)
0.9 (1.0)
-1.1 (0.9)
n=7

1.9 (1.4)
0.8 (1.1)
-1.1 (1.7)

3.5 (1.6)
0.7 (0.9)
-3.0 (1.7)
n=22
Esophageal distensibility (mm)
Mean at baseline2
Mean at week 12 (LOCF)
Mean change from baseline to week 12 (LOCF)

16.2
17.6
1.4
n=5

15.5
15.9
0.2
n=7

16.3
15.1
-1.2
n=5



Conclusion

Improvement in histological and endoscopic parameters as well as esophageal distensibility was achieved in pediatric EoE patients after 12 weeks of treatment with BOS-H and BOS-L, but not with placebo. Greater decreases in histological parameters were observed with BOS-H compared to BOS-L. An additional 12 weeks of open-label BOS-H therapy further improved outcomes in BOS patients with insufficient response during the initial 12-week double-blind therapy. These results suggest that treatment outcome may be further improved beyond 12 weeks of therapy.

Disclosure

AP reports grants from Dr. Falk Pharma GmbH, United Pharmaceuticals, AbbVie and Takeda as well as consulting fees from Dr. Falk Pharma GmbH and speaking fees from Uni‐Pharma Pharmaceuticals Laboratories S.A., Cross Pharmaceuticals, Petsiavas S.A., Nestle, Touch Independent Medical Education, Sanofi-Regeneron Pharmaceuticals and SYN Innovation Laboratories. CG received funding from Dr. Falk Pharma GmbH. NZ received consulting fees from Astra Zeneca, Sanofi-Regeneron and Rafa Inc. as well as speaking fees from Sanofi-Regeneron and Rafa IncSB received speaking fees from Danone, Nutricia, FomF, HiPP, Infectopharm and Nestlé Nutrition Institute and reports advisory board participation for Danone, Dr. Falk Pharma GmbH and Infectopharm. SB and RM are employees of Dr. Falk Pharma. AJL reports consulting fees from Dr. Falk, Esocap; research support from Arena, AstraZeneca, Dr. Falk, EsoCap, Regeneron, Sanofi. JAD reports speaker fees from Capricare, Danone, Ferrer, Takeda; consulting fees from Adacyte. All other authors declare no conflicts of interest.

Conference

UEG Week Barcelona 2026

Topics

Oesophagus

Submission format

Abstract

Session

Risk factors and treatment of eosinophilic esophagitis (Posters)

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Summary: Strategies in proctology: From diagnosis to multidisciplinary management

Summary: Strategies in proctology: From diagnosis to multidisciplinary management

Ugo Grossi Ugo Grossi

The use of PREMs and PROMs to improve the care of patients with liver disease

The use of PREMs and PROMs to improve the care of patients with liver disease

Maria Hjorth Maria Hjorth

Targeting immunometabolism with medical therapies in IBD

Targeting immunometabolism with medical therapies in IBD

Virginia Solitano Virginia Solitano

DECIPHERING THE PRODROME OF INFLAMMATORY BOWEL DISEASE UP TO 10 YEARS BEFORE DISEASE ONSET BY MASSIVELY PARALLEL SEROLOGY

DECIPHERING THE PRODROME OF INFLAMMATORY BOWEL DISEASE UP TO 10 YEARS BEFORE DISEASE ONSET BY MASSIVELY PARALLEL SEROLOGY

Thomas Vogl Thomas Vogl, Saurabh Mehandru, Jean-Frédéric Colombel, Mayte Suarez-Fariñas, Joana Torres, Francesca Petralia, Sacha Gnjatic, Chad K. Porter, Thierry Dervieux, Renee M. Laird, Mark S. Riddle, Jared S. Magee, Melanie Prinzensteiner, Alexandra E. Livanos, Gabriel Innocenti, Arno R. Bourgonje

BUDESONIDE ORAL SUSPENSION IMPROVES HISTOLOGICAL AND ENDOSCOPIC PARAMETERS AND ESOPHAGEAL DISTENSIBILITY IN PEDIATRIC EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 2/3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (PEDEOS-1)

BUDESONIDE ORAL SUSPENSION IMPROVES HISTOLOGICAL AND ENDOSCOPIC PARAMETERS AND ESOPHAGEAL DISTENSIBILITY IN PEDIATRIC EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 2/3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (PEDEOS-1)

Jorge Amil Dias Jorge Amil Dias, Stephan Buderus, Ralph Mueller, Sarah Burrack, Michael Vieth, Noam Zevit, Carolina Gutiérrez Junquera, Michiel van Wijk, Johanna Escher, Shoma Dutt, Marcus Karl-Heinz Auth, Alexandra Papadopoulou, Henedina Antunes, Alfredo J. Lucendo

Association between pancreatic adenocarcinoma and organochlorine pesticides

Association between pancreatic adenocarcinoma and organochlorine pesticides

Ahsen Ustaoglu Ahsen Ustaoglu, Mathias Brugel

UEG Podcast Episode
Journal Podcast
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Association between pancreatic adenocarcinoma and organochlorine pesticides

Mathias Brugel, Ahsen Ustaoglu

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Published

2024

More Like This:

Summary: Strategies in proctology: From diagnosis to multidisciplinary management

Summary: Strategies in proctology: From diagnosis to multidisciplinary management

Ugo Grossi Ugo Grossi

The use of PREMs and PROMs to improve the care of patients with liver disease

The use of PREMs and PROMs to improve the care of patients with liver disease

Maria Hjorth Maria Hjorth

Targeting immunometabolism with medical therapies in IBD

Targeting immunometabolism with medical therapies in IBD

Virginia Solitano Virginia Solitano

DECIPHERING THE PRODROME OF INFLAMMATORY BOWEL DISEASE UP TO 10 YEARS BEFORE DISEASE ONSET BY MASSIVELY PARALLEL SEROLOGY

DECIPHERING THE PRODROME OF INFLAMMATORY BOWEL DISEASE UP TO 10 YEARS BEFORE DISEASE ONSET BY MASSIVELY PARALLEL SEROLOGY

Thomas Vogl Thomas Vogl, Saurabh Mehandru, Jean-Frédéric Colombel, Mayte Suarez-Fariñas, Joana Torres, Francesca Petralia, Sacha Gnjatic, Chad K. Porter, Thierry Dervieux, Renee M. Laird, Mark S. Riddle, Jared S. Magee, Melanie Prinzensteiner, Alexandra E. Livanos, Gabriel Innocenti, Arno R. Bourgonje

BUDESONIDE ORAL SUSPENSION IMPROVES HISTOLOGICAL AND ENDOSCOPIC PARAMETERS AND ESOPHAGEAL DISTENSIBILITY IN PEDIATRIC EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 2/3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (PEDEOS-1)

BUDESONIDE ORAL SUSPENSION IMPROVES HISTOLOGICAL AND ENDOSCOPIC PARAMETERS AND ESOPHAGEAL DISTENSIBILITY IN PEDIATRIC EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 2/3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (PEDEOS-1)

Jorge Amil Dias Jorge Amil Dias, Stephan Buderus, Ralph Mueller, Sarah Burrack, Michael Vieth, Noam Zevit, Carolina Gutiérrez Junquera, Michiel van Wijk, Johanna Escher, Shoma Dutt, Marcus Karl-Heinz Auth, Alexandra Papadopoulou, Henedina Antunes, Alfredo J. Lucendo

Association between pancreatic adenocarcinoma and organochlorine pesticides

Association between pancreatic adenocarcinoma and organochlorine pesticides

Ahsen Ustaoglu Ahsen Ustaoglu, Mathias Brugel

The global reference point for the digestive health community

Platform Publisher

United European Gastroenterology

Wickenburggasse 1 1080 Vienna, Austria

Contact us

support@ueg.eu

ueg.eu

T: +43 1 997 1639

Legal

Terms & Conditions

Imprint

Privacy Policy

Explore

My Bookmarks

My recommendations

My fields of interest

© 2026 United European Gastroenterology

Change fields of interest

These fields are selected based on the interests in your myUEG profile.
Click the item to unselect it. You can select multiple items.